SQZ TAC T1D
Alternative Names: SQZ-TAC-T1DLatest Information Update: 28 Jun 2024
At a glance
- Originator SQZ Biotech
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral)
- 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
- 24 Mar 2021 Pharmacodynamics data from a preclinical studies in Type 1 diabetes mellitus released by SQZ Biotech